Line 1: |
Line 1: |
− | == Myeloproliferative Neoplasms (MPN) == | + | ==Myeloproliferative Neoplasms (MPN)== |
| + | |
| *[[Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive]] | | *[[Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive]] |
| *[[Chronic Neutrophilic Leukemia (CNL)]] | | *[[Chronic Neutrophilic Leukemia (CNL)]] |
Line 8: |
Line 9: |
| *[[Myeloproliferative Neoplasm (MPN), Unclassifiable]] | | *[[Myeloproliferative Neoplasm (MPN), Unclassifiable]] |
| | | |
− | == Mastocytosis == | + | ==Mastocytosis== |
| + | |
| *[[Cutaneous Mastocytosis]] | | *[[Cutaneous Mastocytosis]] |
| *[[Systemic Mastocytosis]] | | *[[Systemic Mastocytosis]] |
| *[[Mast Cell Sarcoma]] | | *[[Mast Cell Sarcoma]] |
| | | |
− | == Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2 == | + | ==Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2== |
| + | |
| *[[Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement]] | | *[[Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement]] |
| *[[Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement]] | | *[[Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement]] |
Line 19: |
Line 22: |
| *[[Myeloid/Lymphoid Neoplasms with PCM1-JAK2]] | | *[[Myeloid/Lymphoid Neoplasms with PCM1-JAK2]] |
| | | |
− | == Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) == | + | ==Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)== |
| + | |
| *[[Chronic Myelomonocytic Leukemia (CMML)]] | | *[[Chronic Myelomonocytic Leukemia (CMML)]] |
| *[[Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]] | | *[[Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]] |
Line 26: |
Line 30: |
| *[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable|MDS/MPN, Unclassifiable]] | | *[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable|MDS/MPN, Unclassifiable]] |
| | | |
− | == Myelodysplastic Syndromes (MDS) == | + | ==Myelodysplastic Syndromes (MDS)== |
| + | |
| *[[Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia|MDS with Single Lineage Dysplasia]] | | *[[Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia|MDS with Single Lineage Dysplasia]] |
| *[[Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)|MDS with Ring Sideroblasts (MDS-RS)]] | | *[[Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)|MDS with Ring Sideroblasts (MDS-RS)]] |
Line 36: |
Line 41: |
| *[[Refractory Cytopenia of Childhood]] | | *[[Refractory Cytopenia of Childhood]] |
| | | |
− | == Myeloid Neoplasms with Germline Predisposition == | + | ==Myeloid Neoplasms with Germline Predisposition== |
| | | |
| *[[Acute Myeloid Leukaemia with Germline CEBPA Mutation]] | | *[[Acute Myeloid Leukaemia with Germline CEBPA Mutation]] |
Line 45: |
Line 50: |
| *[[Myeloid Neoplasms with Germline GATA2 Mutation]] | | *[[Myeloid Neoplasms with Germline GATA2 Mutation]] |
| | | |
− | == Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms == | + | ==Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms== |
| + | |
| *[[Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities|AML with Recurrent Genetic Abnormalities]] | | *[[Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities|AML with Recurrent Genetic Abnormalities]] |
| | | |
Line 83: |
Line 89: |
| - [[Myeloid Leukemia Associated with Down Syndrome]] | | - [[Myeloid Leukemia Associated with Down Syndrome]] |
| | | |
− | == Blastic Plasmacytoid Dendritic Cell Neoplasm == | + | ==Blastic Plasmacytoid Dendritic Cell Neoplasm== |
| + | |
| *[[Blastic Plasmacytoid Dendritic Cell Neoplasm]] | | *[[Blastic Plasmacytoid Dendritic Cell Neoplasm]] |
| | | |
− | == Acute Leukemias of Ambiguous Lineage (MPAL) == | + | ==Acute Leukemias of Ambiguous Lineage (MPAL)== |
| + | |
| *[[Acute Leukemias of Ambiguous Lineage]] | | *[[Acute Leukemias of Ambiguous Lineage]] |
| | | |
Line 97: |
Line 105: |
| - [[Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)]] | | - [[Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)]] |
| | | |
− | == Precursor Lymphoid Neoplasms (B-ALL, T-ALL) == | + | ==Precursor Lymphoid Neoplasms (B-ALL, T-ALL)== |
| + | |
| *[[B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities|B-Lymphoblastic Leukemia/Lymphoma (B-ALL) with Recurrent Genetic Abnormalities]] | | *[[B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities|B-Lymphoblastic Leukemia/Lymphoma (B-ALL) with Recurrent Genetic Abnormalities]] |
| | | |
Line 116: |
Line 125: |
| - [[NK-Lymphoblastic Leukemia/Lymphoma]] | | - [[NK-Lymphoblastic Leukemia/Lymphoma]] |
| | | |
− | == Mature B-Cell Neoplasms (CLL, Plasma Cell Neoplasms, Non-Hodgkin Lymphomas) == | + | ==Mature B-Cell Neoplasms (CLL, Plasma Cell Neoplasms, Non-Hodgkin Lymphomas)== |
| + | |
| *[[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]] | | *[[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]] |
| + | |
| - [[Monoclonal B-cell Lymphocytosis]] | | - [[Monoclonal B-cell Lymphocytosis]] |
| | | |
Line 127: |
Line 138: |
| | | |
| *[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]] | | *[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]] |
| + | |
| - [[Splenic Diffuse Red Pulp Small B-cell Lymphoma]] | | - [[Splenic Diffuse Red Pulp Small B-cell Lymphoma]] |
| - [[Hairy Cell Leukemia Variant]] | | - [[Hairy Cell Leukemia Variant]] |
| | | |
| *[[Lymphoplasmacytic Lymphoma]] | | *[[Lymphoplasmacytic Lymphoma]] |
| + | |
| - [[Waldenstrom Macroglobulinemia]] | | - [[Waldenstrom Macroglobulinemia]] |
| | | |
Line 136: |
Line 149: |
| | | |
| *[[Heavy Chain Diseases]] | | *[[Heavy Chain Diseases]] |
| + | |
| - [[Mu Heavy Chain Disease]] | | - [[Mu Heavy Chain Disease]] |
| - [[Gamma Heavy Chain Disease]] | | - [[Gamma Heavy Chain Disease]] |
Line 141: |
Line 155: |
| | | |
| *[[Plasma Cell Neoplasms]] | | *[[Plasma Cell Neoplasms]] |
| + | |
| - [[Non-IgM Monoclonal Gammopathy of Undetermined Significance]] | | - [[Non-IgM Monoclonal Gammopathy of Undetermined Significance]] |
| - [[Plasma Cell Myeloma]] | | - [[Plasma Cell Myeloma]] |
Line 155: |
Line 170: |
| | | |
| *[[Nodal Marginal Zone Lymphoma]] | | *[[Nodal Marginal Zone Lymphoma]] |
| + | |
| - [[Paediatric Nodal Marginal Zone Lymphoma]] | | - [[Paediatric Nodal Marginal Zone Lymphoma]] |
| | | |
| *[[Follicular Lymphoma]] | | *[[Follicular Lymphoma]] |
| + | |
| - [[Testicular Follicular Lymphoma]] | | - [[Testicular Follicular Lymphoma]] |
| - [[In Situ Follicular Neoplasia]] | | - [[In Situ Follicular Neoplasia]] |
Line 169: |
Line 186: |
| | | |
| *[[Mantle Cell Lymphoma]] | | *[[Mantle Cell Lymphoma]] |
| + | |
| - [[Leukemic Non-Nodal Mantle Cell Lymphoma]] | | - [[Leukemic Non-Nodal Mantle Cell Lymphoma]] |
| - [[In Situ Mantle Cell Neoplasia]] | | - [[In Situ Mantle Cell Neoplasia]] |
Line 185: |
Line 203: |
| | | |
| *[[Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation]] | | *[[Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation]] |
| + | |
| - [[Fibrin-Associated Diffuse Large B-cell Lymphoma]] | | - [[Fibrin-Associated Diffuse Large B-cell Lymphoma]] |
| | | |
Line 200: |
Line 219: |
| | | |
| *[[HHV8-Associated Lymphoproliferative Disorders]] | | *[[HHV8-Associated Lymphoproliferative Disorders]] |
| + | |
| - [[Multicentric Castleman Disease]] | | - [[Multicentric Castleman Disease]] |
| - [[HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]] | | - [[HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]] |
Line 209: |
Line 229: |
| | | |
| *[[High-Grade B-cell Lymphoma]] | | *[[High-Grade B-cell Lymphoma]] |
| + | |
| - [[High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements]] | | - [[High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements]] |
| - [[High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)]] | | - [[High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)]] |
Line 214: |
Line 235: |
| *[[B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma]] | | *[[B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma]] |
| | | |
− | == Mature T- and NK-cell Neoplasms == | + | ==Mature T- and NK-cell Neoplasms== |
| + | |
| *[[T-cell Prolymphocytic Leukemia]] | | *[[T-cell Prolymphocytic Leukemia]] |
| | | |
Line 224: |
Line 246: |
| | | |
| *[[EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]] | | *[[EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]] |
| + | |
| - [[Systemic EBV-Positive T-cell Lymphoma of Childhood]] | | - [[Systemic EBV-Positive T-cell Lymphoma of Childhood]] |
| - [[Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form]] | | - [[Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form]] |
Line 234: |
Line 257: |
| | | |
| *[[Intestinal T-cell Lymphoma]] | | *[[Intestinal T-cell Lymphoma]] |
| + | |
| - [[Enteropathy-Associated T-cell Lymphoma]] | | - [[Enteropathy-Associated T-cell Lymphoma]] |
| - [[Monomorphic Epitheliotropic Intestinal T-cell Lymphoma]] | | - [[Monomorphic Epitheliotropic Intestinal T-cell Lymphoma]] |
Line 248: |
Line 272: |
| | | |
| *[[Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders]] | | *[[Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders]] |
| + | |
| - [[Lymphomatoid Papulosis]] | | - [[Lymphomatoid Papulosis]] |
| - [[Primary Cutaneous Anaplastic Large Cell Lymphoma]] | | - [[Primary Cutaneous Anaplastic Large Cell Lymphoma]] |
| | | |
| *[[Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes]] | | *[[Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes]] |
| + | |
| - [[Primary Cutaneous Gamma Delta T-cell Lymphoma]] | | - [[Primary Cutaneous Gamma Delta T-cell Lymphoma]] |
| - [[Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma]] | | - [[Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma]] |
Line 260: |
Line 286: |
| | | |
| *[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]] | | *[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]] |
| + | |
| - [[Angioimmunoblastic T-cell Lymphoma]] | | - [[Angioimmunoblastic T-cell Lymphoma]] |
| - [[Follicular T-cell Lymphoma]] | | - [[Follicular T-cell Lymphoma]] |
Line 270: |
Line 297: |
| *[[Breast Implant-Associated Anaplastic Large Cell Lymphoma]] | | *[[Breast Implant-Associated Anaplastic Large Cell Lymphoma]] |
| | | |
− | == Hodgkin Lymphomas== | + | ==Hodgkin Lymphomas== |
| + | |
| *[[Nodular Lymphocyte Predominant Hodgkin Lymphoma]] | | *[[Nodular Lymphocyte Predominant Hodgkin Lymphoma]] |
| | | |
− | *[[Classic Hodgkin Lymphoma]] | + | *Classic Hodgkin Lymphoma |
| + | |
| - [[Nodular Sclerosis Classic Hodgkin Lymphoma]] | | - [[Nodular Sclerosis Classic Hodgkin Lymphoma]] |
| - [[Lymphocyte-Rich Classic Hodgkin Lymphoma]] | | - [[Lymphocyte-Rich Classic Hodgkin Lymphoma]] |
Line 279: |
Line 308: |
| - [[Lymphocyte-Depleted Classic Hodgkin Lymphoma]] | | - [[Lymphocyte-Depleted Classic Hodgkin Lymphoma]] |
| | | |
− | == Immunodeficiency-Associated Lymphoproliferative Disorders== | + | ==Immunodeficiency-Associated Lymphoproliferative Disorders== |
| + | |
| *[[Lymphomas Associated with HIV Infection]] | | *[[Lymphomas Associated with HIV Infection]] |
| | | |
| *[[Post-Transplant Lymphoproliferative Disorders]] | | *[[Post-Transplant Lymphoproliferative Disorders]] |
| + | |
| - [[Non-Destructive Post-Transplant Lymphoproliferative Disorders]] | | - [[Non-Destructive Post-Transplant Lymphoproliferative Disorders]] |
| - [[Polymorphic Post-Transplant Lymphoproliferative Disorders]] | | - [[Polymorphic Post-Transplant Lymphoproliferative Disorders]] |
Line 292: |
Line 323: |
| *[[Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders]] | | *[[Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders]] |
| | | |
− | == Histiocytic and Dendritic Cell Neoplasms == | + | ==Histiocytic and Dendritic Cell Neoplasms== |
| + | |
| *[[Histiocytic Sarcoma]] | | *[[Histiocytic Sarcoma]] |
| | | |
| *[[Tumors Derived From Langerhans Cells]] | | *[[Tumors Derived From Langerhans Cells]] |
| + | |
| - [[Langerhans Cell Histiocytosis]] | | - [[Langerhans Cell Histiocytosis]] |
| - [[Langerhans Cell Sarcoma]] | | - [[Langerhans Cell Sarcoma]] |
Line 304: |
Line 337: |
| | | |
| *[[Follicular Dendritic Cell Sarcoma]] | | *[[Follicular Dendritic Cell Sarcoma]] |
| + | |
| - [[Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma]] | | - [[Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma]] |
| | | |